Quanterix’ Simoa Technology To Support Myriad Rbm’s New Immunoassay Services
Lexington, MA – Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), will use Quanterix’ Simoa technology to launch new ultrasensitive immunoassay services in its CLIA-certified laboratory in Austin, Texas. Using Simoa, the company will have the ability to accurately measure protein biomarkers that were previously difficult or even impossible to detect in blood samples.
“The Simoa platform is an exciting new tool that is 100 to 1,000 times more sensitive than conventional tests for blood-based protein biomarkers and will open up new avenues of clinical research,” said Ralph McDade, President of Myriad RBM. “We believe Simoa will significantly accelerate biomedical discoveries by providing researchers with valuable insights into both the underlying mechanisms of disease and the safety and efficacy of pharmaceuticals.”
Initially, Myriad RBM will offer Simoa assay services for the study of inflammatory and autoimmune diseases. The Company has manufactured and validated Simoa–based quantitative immunoassays for interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) which includes carefully designed calibrators and controls to provide multiple measurements of quality, precision and accuracy. Myriad RBM plans to add more Simoa–based immunoassays throughout the year.
Myriad RBM’s experience and infrastructure offering validated assays in a CLIA-certified laboratory complement Quanterix’ own Simoa service offering in their Accelerator based in Lexington, MA. Quanterix’ Accelerator allows researchers to access Simoa technology to run their samples on Simoa assays, convert their existing assays to Simoa for greater sensitivity, or to have custom assays developed by Quanterix personnel for specific markers of interest.
“Understanding the incredible role of quantifying ultra-low concentrations of protein biomarkers in human samples and their linkage to the complex mechanisms of a disease has the potential to revolutionize the field of medicine as we know it,” said Kevin Hrusovsky, CEO and Executive Chairman, Quanterix. “We are very pleased to be collaborating with Myriad RBM and to work together to provide access to these important new developments in healthcare.”
Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: www.quanterix.com.
Nikki Festa & Caitlyn Keating
Share this page